MARLBOROUGH, Mass.,
March 25, 2019 /PRNewswire/
-- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology
company developing the next generation of immuno-oncology
therapeutics based on its proprietary self-delivering RNAi
(sd-rxRNA®) therapeutic platform, announced today that
the Company will present a poster at the American Association for
Cancer Research (AACR) Annual Meeting 2019, which will be held from
March 29–April 1, 2019 at the Georgia World Congress Center in
Atlanta, Georgia.
Logo:
https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
The details of the presentation are as follows:
Poster #: 1963
Poster Title: Feasibility and efficacy using self-delivering
RNAi against TGFB1 to reduce TME immunosuppression
Session: Secreted Changes in the Tumor Microenvironment:
Exosomes and Chemokines
Date and Time: Monday, April 1,
2019, 1:00 p.m.–5:00 p.m. Eastern Time
Location: Hall B, Poster Section 6
The poster will be presented by Dr. Winnie Tam, Director of Pharmacology, and will
also be available under the "Investors–Events and Presentations"
section of the Company's website, www.phiopharma.com, approximately
one hour following the presentation.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology
company developing the next generation of immuno-oncology
therapeutics based on its self-delivering RNAi (sd-rxRNA®)
therapeutic platform. The Company's discovery and research efforts
are focused on developing sd-rxRNA therapeutic compounds to be used
in the context of adoptive cell transfer by targeting checkpoints
or other gene targets, or to be used in immunotherapy following
intratumoral injection. We aim to maximize the power of our
sd-rxRNA therapeutic compounds by weaponizing therapeutic immune
effector cells to attack cancer, and to make tumors more
susceptible to such attacks, and ultimately provide patients
battling cancers with a powerful new treatment option that goes
beyond current treatment modalities. For additional information,
visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are neither historical facts nor
assurances of future performance. These statements are based only
on our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results may
differ materially from those indicated in the forward-looking
statements as a result of a number of important factors, including,
but not limited to, the safety and efficacy of our product
candidates, future success of our clinical trials and scientific
studies, expected duration of available cash runway, our ability to
enter into strategic partnerships and the future success of these
strategic partnerships, the availability of funds and resources to
pursue our research and development projects and general economic
conditions. Our Annual Report on Form 10-K and subsequent
Quarterly Reports on Form 10-Q include detailed risks under the
caption "Risk Factors" that may affect our business, results of
operations and financial condition. Readers are urged to review
these risk factors and to not act in reliance on any
forward-looking statements, as actual results may differ from those
contemplated by our forward-looking statements. Phio does not
undertake to update forward-looking statements to reflect a change
in its views, events or circumstances that occur after the date of
this release.
Contact
Phio Pharmaceuticals Corp.
ir@phiopharma.com
View original
content:http://www.prnewswire.com/news-releases/phio-pharmaceuticals-to-present-poster-on-the-use-of-self-delivering-rnai-in-immuno-oncology-at-the-aacr-annual-meeting-2019-300817442.html
SOURCE Phio Pharmaceuticals Corp.